WASHINGTON, D.C. (October 27, 2021) — Kenneth Westberry has joined the Association for Accessible Medicines as Senior Manager, State Government Affairs. He will assist AAM’s state government affairs team with strategic, operational and administrative support in pursuit of its advocacy goals and in representing the generics and biosimilars industry across the country.
Legislative efforts to address the cost of prescription drugs and the pharmaceutical supply chain are now occurring in every state. Kenneth’s experience and skill set will bolster our advocacy across the country, said Erik Komendant, Senior Vice President, Government Affairs.
We are excited to welcome Kenneth to the team and to have him join our efforts to increase patient access to more affordable generic and biosimilar medicines.
Kenneth comes to AAM from the National Coalition of STD Directors, where he served as Senior Manager, Policy and Government Relations. He previously served as Manager, Legislative Affairs at the U.S. Chamber of Commerce, Institute for Legal Reform, and as a Public Policy Associate for the Southern Center for Human Rights and Georgia Justice Project. He co-founded the government relations and communications firm Shatterless Strategies.
Kenneth holds a BA in Political Science from Davidson College and a JD from Emory University School of Law.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.